SOCS3 is a critical negative regulator of cytokine signaling that inhibits JAK/STAT pathway activation by binding to receptor tyrosine kinases and directly suppressing JAK2 kinase activity 1. This negative feedback mechanism is essential for immune homeostasis; reduced SOCS3 expression characterizes multiple pathological conditions. In rheumatoid arthritis, SOCS3 expression is significantly decreased compared to healthy controls, correlating with immune dysregulation 2. SOCS3 functions as a tumor suppressor in multiple cancers: low expression in hepatocellular carcinoma promotes JAK2/STAT3 activation and metastasis 1, while reduced SOCS3 in cholangiocarcinoma associates with poor prognosis and metastatic disease 3. Similarly, in prostate cancer, SOCS3 upregulation correlates with favorable outcomes and reduced recurrence 4. SOCS3 also regulates allergic responses, with genetic variants affecting Th2 cell proliferation and IL-4 levels in atopic diseases 5. In inflammatory conditions like ossification of ligamentum flavum, SOCS3 downregulation is associated with increased immune infiltration 6. Clinically, JAK inhibitors targeting SOCS1/SOCS3-regulated pathways have been approved for atopic dermatitis and psoriasis 7. SOCS3 regulation occurs through posttranscriptional mechanisms including mRNA decay rather than genetic mutations or DNA methylation 8.